Research map: Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study

Back to the article

Papers in this map

  1. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities · Yuxiong Jiang · 2023 · 113 citations · Cited by this paper
  2. Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the APEX study · 2026 · Related
  3. Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis · Joel M. Gelfand · 2022 · 50 citations · Cited by this paper
  4. Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease · 2026 · Related
  5. Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis · Teppei Hagino · 2023 · 37 citations · Cited by this paper
  6. Anakinra treatment practices in colchicine-resistant familial Mediterranean fever: a survey of pediatric rheumatologists conducted through the PReS AID-WP and the Turkish pediatric rheumatology associations · 2026 · Related
  7. Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-α, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study · Teng‐Li Lin · 2025 · 34 citations · Cited by this paper
  8. Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications · 2026 · Related
  9. The Impact of Treatment with IL-17/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and/or Psoriatic Arthritis: A Systematic Review · Aikaterini Tsiogka · 2023 · 31 citations · Cited by this paper
  10. Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials · 2026 · Related
  11. Skin Inflammation, Systemic Inflammation, and Cardiovascular Disease in Psoriasis · Axel Svedbom · 2024 · 28 citations · Cited by this paper
  12. The role of monoclonal antibodies in the treatment of lupus nephritis · 2026 · Related
  13. Cardiovascular Considerations and Implications for Treatment in Psoriasis: An Updated Review · Hitaishi Mehta · 2024 · 24 citations · Cited by this paper
  14. Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China · 2026 · Related
  15. Relationship between plasma atherogenic index and incidence of cardiovascular diseases in Chinese middle-aged and elderly people · Mengjie Zhao · 2025 · 23 citations · Cited by this paper
  16. Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats · 2026 · Related
  17. Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study · Kevin E. Boczar · 2023 · 17 citations · Cited by this paper
  18. Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma · 2026 · Related
  19. Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities · Luca Potestio · 2024 · 16 citations · Cited by this paper
  20. Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry · 2026 · Related
  21. Biomarkers in Psoriasis: The Future of Personalised Treatment · Bikash Ranjan Kar · 2024 · 15 citations · Cited by this paper
  22. Cardiovascular risk in psoriatic arthritis: How can we manage it? · Fabiola Atzeni · 2025 · 15 citations · Cited by this paper
  23. Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis · Tai‐Li Chen · 2024 · 14 citations · Cited by this paper
  24. Cardiovascular comorbidities in psoriatic arthritis: state of the art · Mrinalini Dey · 2024 · 13 citations · Cited by this paper
  25. Biologic Therapy and Cardiometabolic Risk in Psoriasis: A Retrospective Review · Annika D. Smith · 2025 · 11 citations · Cited by this paper
  26. Residual Inflammation in Patients with Psoriasis Treated with Biologic Therapy: Findings from 3 Prospective Observational Cohorts · Alba Lecumberri · 2025 · 11 citations · Cited by this paper
  27. The Association Between Psoriasis and Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis of Observational Studies · Pacelli C Osigwe · 2024 · 10 citations · Cited by this paper
  28. The role of lipidomics in psoriasis · Dominika Boboryko · 2025 · 9 citations · Cited by this paper
  29. Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis · Varitsara Mangkorntongsakul · 2025 · 7 citations · Cited by this paper
  30. Exploring the Link Between Psoriasis and Adipose Tissue: One Amplifies the Other · Roberta Di Caprio · 2024 · 6 citations · Cited by this paper
  31. Anti-IL-17 and Anti-IL-23 Therapies Modulate Serum Biomarkers of Intestinal Dysbiosis and Oxidative Stress Linked to Cardiovascular Risk in Patients with Psoriasis · Giuseppe Annunziata · 2025 · 5 citations · Cited by this paper
  32. Calculated small dense LDL-cholesterol and its correlation with the atherogenic index of plasma · Sojit Tomo · 2022 · 3 citations · Cited by this paper
  33. Associations between the atherogenic index of plasma and psoriasis among US adults: A cross-sectional study based on NHANES 2009 to 2014 · Yanan Tuo · 2024 · 3 citations · Cited by this paper
  34. Do patients with psoriasis are at higher risk for atherogenity? A case–control study · Hakan Aksoy · 2022 · 2 citations · Cited by this paper
  35. Science to Clinical Practice: IL-23 Inhibition for the Treatment of Psoriasis. Latest Insights on the Selective Mode of Action of Risankizumab · Caro Cross · 2025 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)